サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：ブルガダ症候群の世界市場 - 市場シェア、規模、動向、産業分析：診断別、治療別、最終用途別、地域別、セグメント予測（2023年～2032年）
市場調査レポート
商品コード
1238769

ブルガダ症候群の世界市場 - 市場シェア、規模、動向、産業分析：診断別、治療別、最終用途別、地域別、セグメント予測（2023年～2032年）

Brugada Syndrome Market Share, Size, Trends, Industry Analysis Report, By Diagnosis (Electrocardiogram, Electrophysiology test, Genetic testing); By Treatment; By End-Use; By Region; Segment Forecast, 2023 - 2032
出版日: | 発行: Polaris Market Research | ページ情報: 英文 116 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
ブルガダ症候群の世界市場 - 市場シェア、規模、動向、産業分析：診断別、治療別、最終用途別、地域別、セグメント予測（2023年～2032年）
出版日: 2023年02月01日
発行: Polaris Market Research
ページ情報: 英文 116 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のブルガダ症候群の市場規模は、2032年までに23億8,000万米ドルに達すると予想されています。

当レポートでは、世界のブルガダ症候群市場を調査しており、市場の概要、市場規模や予測、動向、促進要因・抑制要因、診断別・治療別・最終用途別・地域別などの分析、さらに企業プロファイルなどを提供しています。

目次

第1章 イントロダクション

  • レポートの説明
    • 調査の目的
    • 市場範囲
    • 前提条件
  • 利害関係者

第2章 エグゼクティブサマリー

  • 市場のハイライト

第3章 調査手法

  • 概要
    • データマイニング
  • 情報源
    • 一次情報
    • 二次情報

第4章 世界のブルガダ症候群市場の洞察

  • ブルガダ症候群市場 - 業界のスナップショット
  • ブルガダ症候群市場力学
    • 促進要因と機会
    • 抑制要因と課題
  • ポーターのファイブフォース分析
    • 供給企業の交渉力
    • 新規参入者の脅威
    • 買い手の交渉力
    • 代替品の脅威
    • 既存企業間の競争力
  • PESTEL分析
  • ブルガダ症候群の業界動向
  • バリューチェーン分析
  • COVID-19影響分析

第5章 世界のブルガダ症候群市場：診断別

  • 主な調査結果
  • イントロダクション
    • 世界のブルガダ症候群市場、診断別（2019年～2032年）
  • 心電図
    • 世界のブルガダ症候群市場、心電図別、地域別（2019年～2032年）
  • 電気生理学検査
    • 世界のブルガダ症候群市場、電気生理学検査別、地域別（2019年～2032年）
  • 遺伝子検査
    • 世界のブルガダ症候群市場、遺伝子検査別、地域別（2019年～2032年）
  • その他
    • 世界のブルガダ症候群市場、その他別、地域別（2019年～2032年）

第6章 世界のブルガダ症候群市場：治療別

  • 主な調査結果
  • イントロダクション
    • 世界のブルガダ症候群市場、治療別（2019年～2032年）
  • 埋め込み型除細動器
    • 世界のブルガダ症候群市場、埋め込み型除細動器別、地域別（2019年～2032年）
  • 薬物療法
    • 世界のブルガダ症候群市場、薬物療法別、地域別（2019年～2032年）
    • 抗不整脈薬
    • 向精神薬
    • 麻酔薬・鎮痛薬
  • その他
    • 世界のブルガダ症候群市場、その他別、地域別（2019年～2032年）

第7章 世界のブルガダ症候群市場：最終用途別

  • 主な調査結果
  • イントロダクション
    • 世界のブルガダ症候群市場、最終用途別（2019年～2032年）
  • 病院・診療所
    • 世界のブルガダ症候群市場、病院・診療所別、地域別（2019年～2032年）
  • 外科センター
    • 世界のブルガダ症候群市場、外科センター別、地域別（2019年～2032年）
  • 診断センター
    • 世界のブルガダ症候群市場、診断センター別、地域別（2019年～2032年）
  • その他
    • 世界のブルガダ症候群市場、その他別、地域別（2019年～2032年）

第8章 世界のブルガダ症候群市場：地域別

  • 主な調査結果
  • イントロダクション
    • ブルガダ症候群市場評価、地域別（2019年～2032年）
  • ブルガダ症候群市場 - 北米
    • 北米：ブルガダ症候群市場、診断別（2019年～2032年）
    • 北米：ブルガダ症候群市場、最終用途別（2019年～2032年）
    • 北米：ブルガダ症候群市場、治療別（2019年～2032年）
    • ブルガダ症候群市場 - 米国
    • ブルガダ症候群市場 - カナダ
  • ブルガダ症候群市場 - 欧州
    • 欧州：ブルガダ症候群市場、診断別（2019年～2032年）
    • 欧州：ブルガダ症候群市場、最終用途別（2019年～2032年）
    • 欧州：ブルガダ症候群市場、治療別（2019年～2032年）
    • ブルガダ症候群市場 - 英国
    • ブルガダ症候群市場 - フランス
    • ブルガダ症候群市場 - ドイツ
    • ブルガダ症候群市場 - イタリア
    • ブルガダ症候群市場 - スペイン
    • ブルガダ症候群市場 - オランダ
    • ブルガダ症候群市場 - ロシア
  • ブルガダ症候群市場 - アジア太平洋
    • アジア太平洋：ブルガダ症候群市場、診断別（2019年～2032年）
    • アジア太平洋：ブルガダ症候群市場、最終用途別（2019年～2032年）
    • アジア太平洋：ブルガダ症候群市場、治療別（2019年～2032年）
    • ブルガダ症候群市場 - 中国
    • ブルガダ症候群市場 - インド
    • ブルガダ症候群市場 - マレーシア
    • ブルガダ症候群市場 - 日本
    • ブルガダ症候群市場 - インドネシア
    • ブルガダ症候群市場 - 韓国
  • ブルガダ症候群市場 - 中東・アフリカ
    • 中東・アフリカ：ブルガダ症候群市場、診断別（2019年～2032年）
    • 中東・アフリカ：ブルガダ症候群市場、最終用途別（2019年～2032年）
    • 中東・アフリカ：ブルガダ症候群市場、治療別（2019年～2032年）
    • ブルガダ症候群市場 - サウジアラビア
    • ブルガダ症候群市場 - アラブ首長国連邦
    • ブルガダ症候群市場 - イスラエル
    • ブルガダ症候群市場 - 南アフリカ
  • ブルガダ症候群市場 - ラテンアメリカ
    • ラテンアメリカ：ブルガダ症候群市場、診断別（2019年～2032年）
    • ラテンアメリカ：ブルガダ症候群市場、最終用途別（2019年～2032年）
    • ラテンアメリカ：ブルガダ症候群市場、治療別（2019年～2032年）
    • ブルガダ症候群市場 - メキシコ
    • ブルガダ症候群市場 - ブラジル
    • ブルガダ症候群市場 - アルゼンチン

第9章 競合情勢

  • 拡大と買収の分析
    • 拡大
    • 買収
  • パートナーシップ/コラボレーション/協定/公開

第10章 企業プロファイル

  • Abbott
  • Boehringer Ingelheim International
  • Catalyst Pharmaceuticals Inc
  • Ionis Pharmaceuticals
  • Leadiant Biosciences Inc
  • Natera Inc
  • Novo Nordisk A/S
  • Pfizer Inc
  • PTC Therapeutics
  • Roche
  • Salarius Pharmaceuticals Inc
  • Takeda Pharmaceuticals
  • Novartis AG
図表

List of Tables

  • Table 1 Global Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 2 Global Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
  • Table 3 Global Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
  • Table 4 Brugada Syndrome Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 5 North America: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 6 North America: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
  • Table 7 North America: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
  • Table 8 U.S.: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 9 U.S.: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
  • Table 10 U.S.: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
  • Table 11 Canada: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 12 Canada: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
  • Table 13 Canada: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
  • Table 14 Europe: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 15 Europe: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
  • Table 16 Europe: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
  • Table 17 UK: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 18 UK: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
  • Table 19 UK: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
  • Table 20 France: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 21 France: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
  • Table 22 France: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
  • Table 23 Germany: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 24 Germany: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
  • Table 25 Germany: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
  • Table 26 Italy: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 27 Italy: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
  • Table 28 Italy: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
  • Table 29 Spain: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 30 Spain: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
  • Table 31 Spain: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
  • Table 32 Netherlands: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 33 Netherlands: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
  • Table 34 Netherlands: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
  • Table 35 Russia: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 36 Russia: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
  • Table 37 Russia: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
  • Table 38 Asia Pacific: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 39 Asia Pacific: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
  • Table 40 Asia Pacific: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
  • Table 41 China: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 42 China: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
  • Table 43 China: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
  • Table 44 India: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 45 India: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
  • Table 46 India: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
  • Table 47 Malaysia: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 48 Malaysia: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
  • Table 49 Malaysia: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
  • Table 50 Japan: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 51 Japan: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
  • Table 52 Japan: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
  • Table 53 Indonesia: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 54 Indonesia: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
  • Table 55 Indonesia: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
  • Table 56 South Korea: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 57 South Korea: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
  • Table 58 South Korea: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
  • Table 59 Middle East & Africa: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 60 Middle East & Africa: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
  • Table 61 Middle East & Africa: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
  • Table 62 Saudi Arabia: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 63 Saudi Arabia: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
  • Table 64 Saudi Arabia: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
  • Table 65 UAE: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 66 UAE: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
  • Table 67 UAE: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
  • Table 68 Israel: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 69 Israel: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
  • Table 70 Israel: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
  • Table 71 South Africa: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 72 South Africa: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
  • Table 73 South Africa: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
  • Table 74 Latin America: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 75 Latin America: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
  • Table 76 Latin America: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
  • Table 77 Mexico: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 78 Mexico: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
  • Table 79 Mexico: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
  • Table 80 Brazil: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 81 Brazil: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
  • Table 82 Brazil: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
  • Table 83 Argentina: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 84 Argentina: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
  • Table 85 Argentina: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)

List of Figures

  • Figure 1. Global Brugada Syndrome Market, 2019-2032 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Treatment
  • Figure 7. Global Brugada Syndrome Market, by Treatment, 2021 & 2030 (USD Billion)
  • Figure 8. Market by Diagnosis
  • Figure 9. Global Brugada Syndrome Market, by Diagnosis, 2021 & 2030 (USD Billion)
  • Figure 10. Market by End-Use
  • Figure 11. Global Brugada Syndrome Market, by End-Use, 2021 & 2030 (USD Billion)
  • Figure 12. Brugada Syndrome Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Figure 13. Strategic Analysis - Brugada Syndrome Market
目次
Product Code: PM3032

The global brugada syndrome market size is expected to reach USD 2.38 billion by 2032, according to a new study by Polaris Market Research. The report "Brugada Syndrome Market Share, Size, Trends, Industry Analysis Report, By Diagnosis (Electrocardiogram, Electrophysiology, Genetic testing, Others); By Treatment; By End-User; By Region; Segment Forecast, 2023 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Factors driving the worldwide Brugada syndrome treatment market include an increase in the incidence of the disease, an increase in healthcare spending, an increase in therapeutic demand, advancements in diagnostic technology, and increased government activities to raise awareness. Other reasons that contribute to market expansion include the influence of addiction to smoking, changes in lifestyle, and western culture among adults. Furthermore, exposure to hazardous chemicals and environmental pollution drives market expansion.

According to World Health Organization (WHO) estimates, as of 2019, 17.9 million people died as a result of cardiovascular diseases, accounting for more than 32% of all global fatalities. Furthermore, heart attacks and stroke account for approximately 85% of CVD-related fatalities.

According to The National Organization for Rare Disorders, the frequency of Brugada Syndrome in the United States was projected to be 5 in 10,000 persons in 2019. Furthermore, increased awareness of genetic disorders, as well as a burgeoning pharmaceutical and biotechnology sector, will provide attractive growth opportunities for the market throughout the forecast period.

The demand for heart transplantation has increased considerably in recent years due to a rise in the prevalence of heart failure. However, the failure to meet current demand has resulted in a global scarcity of eligible organs for transplantation. According to the National Database of the Health Coffers and Services Administration of the United States, there were around 4150 campaigners on the heart transplant staying list, as of March 2020.

Brugada syndrome has progressed from an uncommon disorder to the second biggest cause of death among young adults in some countries, after only vehicle accidents. The syndrome, which is electrocardiographically characterized by distinct Pulmonary hypertension in the right precordial leads, is associated with a considerable risk of sudden cardiac death in young and otherwise healthy adults, but less typically in newborns and children.

Brugada Syndrome Market Report Highlights:

  • The hospital & clinics sector segment has contributed immensely due to the availability and accessibility of novel therapies and equipment.
  • Implantable cardioverter defibrillator treatment is expected to witness significant growth over the forecast period owing to wide use of this treatment in BrS. It is known to be a significant cause of sudden cardiac mortality in young people.
  • North America dominates the revenue share and is primarily driven by the rising use of electrocardiograms, electrophysiology (EP) tests for illness diagnosis, and a large population base diagnosed with heart-related ailments.
  • The global players include: Abbott, Boehringer Ingelheim, Catalyst Pharmaceuticals, Ionis Pharmaceuticals, Leadiant Biosciences, Natera, Novo Nordisk, Pfizer, PTC Therapeutics, Roche, Salarius Pharmaceuticals, Takeda Pharmaceuticals, Novartis.

Polaris Market Research has segmented the Brugada market report based on diagnosis, treatment, end-use, and region:

Brugada Syndrome, Diagnosis Outlook (Revenue - USD Billion, 2019 - 2032)

  • Electrocardiogram
  • Electrophysiology test
  • Genetic testing
  • Others

Brugada Syndrome, Treatment Outlook (Revenue - USD Billion, 2019 - 2032)

  • Implantable cardioverter defibrillator
  • Drug Therapy
  • Antiarrhythmic Drugs
  • Psychotropic Drugs
  • Anesthetics/Analgesics
  • Others

Brugada Syndrome, End-Use Outlook (Revenue - USD Billion, 2019 - 2032)

  • Hospitals and clinics
  • Surgical centers
  • Diagnostic centers
  • Others

Brugada Syndrome, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Russia
    • Netherlands
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Indonesia
    • Malaysia
  • Latin America
    • Argentina
    • Brazil
    • Mexico
  • Middle East & Africa
    • UAE
    • Saudi Arabia
    • Israel
    • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Brugada Syndrome Market Insights

  • 4.1. Brugada Syndrome Market - Industry Snapshot
  • 4.2. Brugada Syndrome Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rising frequency of cardiac illnesses
      • 4.2.1.2. Growing availability of diagnostic services
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High cost associated with the treatment of brugada syndrome
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Brugada Syndrome Industry Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Brugada Syndrome Market, by Diagnosis

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
  • 5.3. Electrocardiogram
    • 5.3.1. Global Brugada Syndrome Market, by Electrocardiogram, by Region, 2019-2032 (USD Billion)
  • 5.4. Electrophysiology test
    • 5.4.1. Global Brugada Syndrome Market, Electrophysiology test, by Region, 2019-2032 (USD Billion)
  • 5.5. Genetic testing
    • 5.5.1. Global Brugada Syndrome Market, Genetic testing, by Region, 2019-2032 (USD Billion)
  • 5.6. Others
    • 5.6.1. Global Brugada Syndrome Market, Others, by Region, 2019-2032 (USD Billion)

6. Global Brugada Syndrome Market, by Treatment

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
  • 6.3. Implantable cardioverter defibrillator
    • 6.3.1. Global Brugada Syndrome Market, by Implantable cardioverter defibrillator, by Region, 2019-2032 (USD Billion)
  • 6.4. Drug Therapy
    • 6.4.1. Global Brugada Syndrome Market, by Drug Therapy, by Region, 2019-2032 (USD Billion)
    • 6.4.2. Antiarrhythmic Drugs
      • 6.4.2.1. Global Brugada Syndrome Market, by Antiarrhythmic Drugs, by Region, 2019-2032 (USD Billion)
    • 6.4.3. Psychotropic Drugs
      • 6.4.3.1. Global Brugada Syndrome Market, by Psychotropic Drugs, by Region, 2019-2032 (USD Billion)
    • 6.4.4. Anaesthetics/Analgesics
      • 6.4.4.1. Global Brugada Syndrome Market, by Anaesthetics/Analgesics, by Region, 2019-2032 (USD Billion)
  • 6.5. Others
    • 6.5.1. Global Brugada Syndrome Market, by Others, by Region, 2019-2032 (USD Billion)

7. Global Brugada Syndrome Market, by End-Use

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
  • 7.3. Hospitals and clinics
    • 7.3.1. Global Brugada Syndrome Market, by Hospitals and clinics, By Region, 2019-2032 (USD Billion)
  • 7.4. Surgical centers
    • 7.4.1. Global Brugada Syndrome Market, by Surgical centers, By Region, 2019-2032 (USD Billion)
  • 7.5. Diagnostic centers
    • 7.5.1. Global Brugada Syndrome Market, by Diagnostic centers, By Region, 2019-2032 (USD Billion)
  • 7.6. Others
    • 7.6.1. Global Brugada Syndrome Market, by Others, By Region, 2019-2032 (USD Billion)

8. Global Brugada Syndrome Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Brugada Syndrome Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 8.3. Brugada Syndrome Market - North America
    • 8.3.1. North America: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
    • 8.3.2. North America: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
    • 8.3.3. North America: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
    • 8.3.4. Brugada Syndrome Market - U.S.
      • 8.3.4.1. U.S.: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
      • 8.3.4.2. U.S.: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
      • 8.3.4.3. U.S.: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
    • 8.3.5. Brugada Syndrome Market - Canada
      • 8.3.5.1. Canada: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
      • 8.3.5.2. Canada.: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
      • 8.3.5.3. Canada: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
  • 8.4. Brugada Syndrome Market - Europe
    • 8.4.1. Europe: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
    • 8.4.2. Europe.: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
    • 8.4.3. Europe: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
    • 8.4.4. Brugada Syndrome Market - UK
      • 8.4.4.1. UK: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
      • 8.4.4.2. UK.: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
      • 8.4.4.3. UK: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
    • 8.4.5. Brugada Syndrome Market - France
      • 8.4.5.1. France: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
      • 8.4.5.2. France.: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
      • 8.4.5.3. France: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
    • 8.4.6. Brugada Syndrome Market - Germany
      • 8.4.6.1. Germany: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
      • 8.4.6.2. Germany.: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
      • 8.4.6.3. Germany: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
    • 8.4.7. Brugada Syndrome Market - Italy
      • 8.4.7.1. Italy: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
      • 8.4.7.2. Italy.: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
      • 8.4.7.3. Italy: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
    • 8.4.8. Brugada Syndrome Market - Spain
      • 8.4.8.1. Spain: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
      • 8.4.8.2. Spain.: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
      • 8.4.8.3. Spain: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
    • 8.4.9. Brugada Syndrome Market - Netherlands
      • 8.4.9.1. Netherlands: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
      • 8.4.9.2. Netherlands.: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
      • 8.4.9.3. Netherlands: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
    • 8.4.10. Brugada Syndrome Market - Russia
      • 8.4.10.1. Russia: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
      • 8.4.10.2. Russia.: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
      • 8.4.10.3. Russia: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
  • 8.5. Brugada Syndrome Market - Asia Pacific
    • 8.5.1. Asia Pacific: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
    • 8.5.2. Asia Pacific.: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
    • 8.5.3. Asia Pacific: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
    • 8.5.4. Brugada Syndrome Market - China
      • 8.5.4.1. China: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
      • 8.5.4.2. China.: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
      • 8.5.4.3. China: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
    • 8.5.5. Brugada Syndrome Market - India
      • 8.5.5.1. India: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
      • 8.5.5.2. India.: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
      • 8.5.5.3. India: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
    • 8.5.6. Brugada Syndrome Market - Malaysia
      • 8.5.6.1. Malaysia: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
      • 8.5.6.2. Malaysia.: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
      • 8.5.6.3. Malaysia: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
    • 8.5.7. Brugada Syndrome Market - Japan
      • 8.5.7.1. Japan: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
      • 8.5.7.2. Japan.: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
      • 8.5.7.3. Japan: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
    • 8.5.8. Brugada Syndrome Market - Indonesia
      • 8.5.8.1. Indonesia: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
      • 8.5.8.2. Indonesia.: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
      • 8.5.8.3. Indonesia: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
    • 8.5.9. Brugada Syndrome Market - South Korea
      • 8.5.9.1. South Korea: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
      • 8.5.9.2. South Korea.: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
      • 8.5.9.3. South Korea: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
  • 8.6. Brugada Syndrome Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
    • 8.6.2. Middle East & Africa.: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
    • 8.6.3. Middle East & Africa: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
    • 8.6.4. Brugada Syndrome Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
      • 8.6.4.2. Saudi Arabia.: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
    • 8.6.5. Brugada Syndrome Market - UAE
      • 8.6.5.1. UAE: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
      • 8.6.5.2. UAE.: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
      • 8.6.5.3. UAE: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
    • 8.6.6. Brugada Syndrome Market - Israel
      • 8.6.6.1. Israel: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
      • 8.6.6.2. Israel.: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
      • 8.6.6.3. Israel: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
    • 8.6.7. Brugada Syndrome Market - South Africa
      • 8.6.7.1. South Africa: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
      • 8.6.7.2. South Africa.: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
      • 8.6.7.3. South Africa: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
  • 8.7. Brugada Syndrome Market - Latin America
    • 8.7.1. Latin America: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
    • 8.7.2. Latin America.: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
    • 8.7.3. Latin America: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
    • 8.7.4. Brugada Syndrome Market - Mexico
      • 8.7.4.1. Mexico: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
      • 8.7.4.2. Mexico.: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
      • 8.7.4.3. Mexico: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
    • 8.7.5. Brugada Syndrome Market - Brazil
      • 8.7.5.1. Brazil: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
      • 8.7.5.2. Brazil.: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
      • 8.7.5.3. Brazil: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
    • 8.7.6. Brugada Syndrome Market - Argentina
      • 8.7.6.1. Argentina: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
      • 8.7.6.2. Argentina.: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
      • 8.7.6.3. Argentina: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. Abbott
    • 10.1.1. Company Overview
    • 10.1.2. Financial PerTreatmentance
    • 10.1.3. Treatment Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Boehringer Ingelheim International
    • 10.2.1. Company Overview
    • 10.2.2. Financial PerTreatmentance
    • 10.2.3. Treatment Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Catalyst Pharmaceuticals Inc
    • 10.3.1. Company Overview
    • 10.3.2. Financial PerTreatmentance
    • 10.3.3. Treatment Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Ionis Pharmaceuticals
    • 10.4.1. Company Overview
    • 10.4.2. Financial PerTreatmentance
    • 10.4.3. Treatment Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Leadiant Biosciences Inc
    • 10.5.1. Company Overview
    • 10.5.2. Financial PerTreatmentance
    • 10.5.3. Treatment Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Natera Inc
    • 10.6.1. Company Overview
    • 10.6.2. Financial PerTreatmentance
    • 10.6.3. Treatment Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Novo Nordisk A/S
    • 10.7.1. Company Overview
    • 10.7.2. Financial PerTreatmentance
    • 10.7.3. Treatment Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Pfizer Inc
    • 10.8.1. Company Overview
    • 10.8.2. Financial PerTreatmentance
    • 10.8.3. Treatment Benchmarking
    • 10.8.4. Recent Development
  • 10.9. PTC Therapeutics
    • 10.9.1. Company Overview
    • 10.9.2. Financial PerTreatmentance
    • 10.9.3. Treatment Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Roche
    • 10.10.1. Company Overview
    • 10.10.2. Financial PerTreatmentance
    • 10.10.3. Treatment Benchmarking
    • 10.10.4. Recent Development
  • 10.11. Salarius Pharmaceuticals Inc
    • 10.11.1. Company Overview
    • 10.11.2. Financial PerTreatmentance
    • 10.11.3. Treatment Benchmarking
    • 10.11.4. Recent Development
  • 10.12. Takeda Pharmaceuticals
    • 10.12.1. Company Overview
    • 10.12.2. Financial PerTreatmentance
    • 10.12.3. Treatment Benchmarking
    • 10.12.4. Recent Development
  • 10.13. Novartis AG
    • 10.13.1. Company Overview
    • 10.13.2. Financial PerTreatmentance
    • 10.13.3. Treatment Benchmarking
    • 10.13.4. Recent Development